• According to Transparency Market Research’s latest report on the global cancer diagnostics market for the historical period 2017–2018 and forecast period 2019–2027, Increasing trend for preventive diagnosis due to escalating prevalence continues, early diagnosis enables better clinical and economical outcomes for patients are projected to drive the global cancer diagnostics market during the forecast period
  • According to the report, the global cancer diagnostics market was valued at US$ 146.2 Bn in 2018 and is anticipated to expand at a CAGR of 8.8% from 2019 to 2027

Request a sample to get extensive insights into the Cancer Diagnostics Market

Increasing trend for preventive diagnosis due to escalating prevalence continues and early diagnosis enables better clinical and economical outcomes for patients: Key Drivers

  • Cancer has a major impact on society across the world. It is one of the leading causes of death across the globe and is more prevalent in developed and emerging markets. According to American Cancer Society data, over 1.7 million new cancer cases are expected to be diagnosed in 2019 in the U.S. According to information published in the European Journal of Cancer, an estimated 3.9 million new cases of cancer and 1.9 million deaths due to the disease were reported in Europe in 2018.
  • The alarming rate of escalating cancer prevalence compels the healthcare providers to rethink of goals of treating cancer and also focus on prevention. This would require cancer diagnostics that are not only specific and sensitive, but also capable of detecting cancer in early stages. As the prevalence of different types of cancer grows globally, it is expected to drive the global cancer diagnostics market.
  • The high cost of treatment for any kind of cancer is a key driver for increasing market for diagnostic tests and procedures. Cancer is a chronic disease and usually incurs expensive treatment along with debilitating pain, disability and in some cases death. An early detection by use of most modern diagnostics enables quick medical decision making and consequent treatment. This ensures that the cancer does not prevail until it becomes very difficult to treat. Therefore, cancer diagnostics have significant role in reduction of treatment costs, lowering of hospitalization stay, and prevention of unavoidable interventions. Early diagnosis does not necessarily mean cost saving in the treatment of disease. It allows early treatment which results into improved quality of life and ‘quality adjusted life years’ (QALY) gained. The life years gained suffices the justification of even costlier cancer diagnostics and thus provides even better outlook for the Cancer Diagnostics Market

Novel Diagnostic Biomarkers Continue To Create New Revenue Stream Boost Market Growth

  • The increased knowledge about specific cancer biomarkers is providing great market opportunity to treat cancer patients through improvement in the detection. The technological advancements in the field of biotechnology have enabled the identification of potential cancer biomarkers and some of these biomarkers have been commercialized.
  • In February 2020, Biocare Medical launched of seven novel IVD immunohistochemistry antibody markers for clinical diagnostics and research applications.
  • In May 2020, BioGenex introduced three new primary immunohistochemistry (IHC) antibodies for cancer diagnosis. The new launch includes: CD8A, CD56, CD163
  • In 2014, Guardant Health introduced GUARDANT360 blood test that sequences patient’s cancer in real-time through genetic profiling of trace fragments of tumor DNA (cell-free DNA).

Lack of Sensitivity and Specificity to Hamper Market

  • The success of any test to be used for screening, diagnostics or monitoring of a cancer is dependent on the specificity and sensitivity demonstrated by the test. The cancer diagnostics have to be specific to screen patients without cancer and sensitive enough to detect presence of even smallest tumor in the body. Presently, more than 1 million prostate biopsies are carried out in the U.S. and most of them are unnecessary or repeat biopsies only to ensure that a patient with cancer is not missed. It is a result of PSA test, not so specific test, being used for screening for prostate cancer. PSA test is being recommended for annual cancer screening by the American Cancer Society and the American Urologic Association. However, on the other hand, the National Cancer Institute, the American College of Physicians, and the U.S. Preventive Services Tasks Force do not recommend PSA test due of lack of evidence about specificity and its usefulness in reducing morbidity or mortality. Similarly, there is need for specific and sensitive biomarkers for detection of each cancer types that can be used for screening on wider population.
  •  Therefore, the growth of cancer diagnostics market is expected to be negatively affected unless specific and highly sensitive diagnostic tests are introduced in the market.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Global Cancer Diagnostics Market: Competitive Landscape

  • This report profiles major players in the global cancer diagnostics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global cancer diagnostics market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global cancer diagnostics market are
    • Abbott
    • Ambry Genetics
    • AstraZeneca plc
    • bioMeriux SA
    • Eli Lilly and Company
    • Genoptix, Inc.
    • GlaxoSmithKline plc
    • F. Hoffmann-La Roche Ltd
    • Pfizer, Inc. 
    • among others

Stuck in a neck-to-neck competition with other brands? Request a custom report on Cancer Diagnostics Market

Global Cancer Diagnostics Market: Key Developments

Key players in the global cancer diagnostics market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global cancer diagnostics market. A few expansion strategies adopted by players operating in the global cancer diagnostics market are:

  • In July 2020, F. Hoffmann-La Roche Ltd launched its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC).
  • In October 2018, NeoGenomics has entered into a definitive agreement to acquire Genoptix for $125 million in cash and 1 million shares of NeoGenomics common stock. The acquisition of Genoptix enhances NeoGenomics’ leadership in the oncology test market, significantly expanding coverage of oncology practices, increasing customer reach, and leaving a better positioned for growth.

The report on the global cancer diagnostics market discussed individual strategies, followed by company profiles of manufacturers of cancer diagnostics. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global cancer diagnostics market.

Global Cancer Diagnostics Market – Segmentation

Method

  • Biopsy
    • Bone Marrow Biopsy
    • Needle Biopsy
    • Endoscopic Biopsy
  • Endoscopy
    • Bronchoscopy
    • Colonoscopy
    • Sigmoidoscopy
    • Colposcopy
    • Others
  • Imaging
    • MRI Scan
    • PET Scan
    • CT Scan
    • Mammography
    • Ultrasound
  • Tumor Biomarker Tests
    • PSA Tests
    • CTC Tests
    • AFP Tests
    • CA 19-9
    • CA 125
    • EGFR
    • HER2
    • CEA
    • BRCA
    • KRAS
    • ALK

Application

  • Blood Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Kidney Cancer
  • Liver Cancer
  • Lung Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

The global cancer diagnostics market was worth US$ 146.2 Bn and is projected to reach a value of US$ 311.1 Bn by the end of 2027

Cancer diagnostics market is anticipated to grow at a CAGR of 8.8% during the forecast period

North America accounted for a major share of the global cancer diagnostics market

Cancer diagnostics market is driven by increasing trend for preventive diagnosis due to escalating prevalence continues, early diagnosis enables better clinical and economical outcomes for patients

Key players in the global cancer diagnostics market include Abbott, Ambry Genetics, AstraZeneca plc, bioMeriux SA, Eli Lilly and Company, Genoptix, Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer, Inc

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objective

    1.4. Research Highlight

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Diagnostics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

        4.1.2. Industry Evolution / Development

    4.2. Overview

    4.3. Market Dynamic

        4.3.1. Driver

        4.3.2. Restraint

        4.3.3. Opportunitie

    4.4. Global Cancer Diagnostics Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Regulatory Scenario and Reimbursement

    5.2. Cancer Epidemiology

    5.3. List of active market participants (suppliers/distributors/manufacturers/vendors)

6. Global Cancer Diagnostics Market Analysis and Forecast, by Method

    6.1. Introduction & Definition

        6.1.1. Key Findings / Development

    6.2. Global Cancer Diagnostics Market Value Forecast, by Method, 2017–2027

        6.2.1. Biopsy

            6.2.1.1. Bone Marrow Biopsy

            6.2.1.2. Needle Biopsy

            6.2.1.3. Endoscopic Biopsy

        6.2.2. Endoscopy

            6.2.2.1. Bronchoscopy

            6.2.2.2. Colonoscopy

            6.2.2.3. Sigmoidoscopy

            6.2.2.4. Colposcopy

            6.2.2.5. Other

        6.2.3. Imaging

            6.2.3.1. MRI Scan

            6.2.3.2. PET Scan

            6.2.3.3. CT Scan

            6.2.3.4. Mammography

            6.2.3.5. Ultrasound

        6.2.4. Tumor Biomarker Test

            6.2.4.1. PSA Test

            6.2.4.2. CTC Test

            6.2.4.3. AFP Test

            6.2.4.4. CA 19-9

            6.2.4.5. CA 125

            6.2.4.6. EGFR

            6.2.4.7. HER2

            6.2.4.8. CEA

            6.2.4.9. BRCA

            6.2.4.10. KRA

            6.2.4.11. ALK

    6.3. Global Cancer Diagnostics Market Attractiveness, by Method

7. Global Cancer Diagnostics Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

        7.1.1. Key Findings / Development

    7.2. Global Cancer Diagnostics Market Value Forecast, by Application, 2017–2027

        7.2.1. Blood Cancer

        7.2.2. Breast Cancer

        7.2.3. Colorectal Cancer

        7.2.4. Kidney Cancer

        7.2.5. Liver Cancer

        7.2.6. Lung Cancer

        7.2.7. Ovarian Cancer

        7.2.8. Pancreatic Cancer

        7.2.9. Prostate Cancer

    7.3. Global Cancer Diagnostics Market Attractiveness, by Application

8. Global Cancer Diagnostics Market Analysis and Forecast, by Region

    8.1. Key Finding

    8.2. Global Cancer Diagnostics Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. North America Cancer Diagnostics Market Attractiveness, by Region

9. North America Cancer Diagnostics Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Finding

    9.2. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027

        9.2.1. Biopsy

            9.2.1.1. Bone Marrow Biopsy

            9.2.1.2. Needle Biopsy

            9.2.1.3. Endoscopic Biopsy

        9.2.2. Endoscopy

            9.2.2.1. Bronchoscopy

            9.2.2.2. Colonoscopy

            9.2.2.3. Sigmoidoscopy

            9.2.2.4. Colposcopy

            9.2.2.5. Other

        9.2.3. Imaging

            9.2.3.1. MRI Scan

            9.2.3.2. PET Scan

            9.2.3.3. CT Scan

            9.2.3.4. Mammography

            9.2.3.5. Ultrasound

        9.2.4. Tumor Biomarker Test

            9.2.4.1. PSA Test

            9.2.4.2. CTC Test

            9.2.4.3. AFP Test

            9.2.4.4. CA 19-9

            9.2.4.5. CA 125

            9.2.4.6. EGFR

            9.2.4.7. HER2

            9.2.4.8. CEA

            9.2.4.9. BRCA

            9.2.4.10. KRA

            9.2.4.11. ALK

    9.3. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027

        9.3.1. Blood Cancer

        9.3.2. Breast Cancer

        9.3.3. Colorectal Cancer

        9.3.4. Kidney Cancer

        9.3.5. Liver Cancer

        9.3.6. Lung Cancer

        9.3.7. Ovarian Cancer

        9.3.8. Pancreatic Cancer

        9.3.9. Prostate Cancer

    9.4. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Cancer Diagnostics Market Attractiveness Analysi

        9.5.1. By Method

        9.5.2. By Application

        9.5.3. By Country

10. Europe Cancer Diagnostics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Finding

    10.2. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027

        10.2.1. Biopsy

            10.2.1.1. Bone Marrow Biopsy

            10.2.1.2. Needle Biopsy

            10.2.1.3. Endoscopic Biopsy

        10.2.2. Endoscopy

            10.2.2.1. Bronchoscopy

            10.2.2.2. Colonoscopy

            10.2.2.3. Sigmoidoscopy

            10.2.2.4. Colposcopy

            10.2.2.5. Other

        10.2.3. Imaging

            10.2.3.1. MRI Scan

            10.2.3.2. PET Scan

            10.2.3.3. CT Scan

            10.2.3.4. Mammography

            10.2.3.5. Ultrasound

        10.2.4. Tumor Biomarker Test

            10.2.4.1. PSA Test

            10.2.4.2. CTC Test

            10.2.4.3. AFP Test

            10.2.4.4. CA 19-9

            10.2.4.5. CA 125

            10.2.4.6. EGFR

            10.2.4.7. HER2

            10.2.4.8. CEA

            10.2.4.9. BRCA

            10.2.4.10. KRA

            10.2.4.11. ALK

    10.3. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027

        10.3.1. Blood Cancer

        10.3.2. Breast Cancer

        10.3.3. Colorectal Cancer

        10.3.4. Kidney Cancer

        10.3.5. Liver Cancer

        10.3.6. Lung Cancer

        10.3.7. Ovarian Cancer

        10.3.8. Pancreatic Cancer

        10.3.9. Prostate Cancer

    10.4. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Europe Cancer Diagnostics Market Attractiveness Analysi

        10.5.1. By Method

        10.5.2. By Application

        10.5.3. By Country/Sub-region

11. Asia Pacific Cancer Diagnostics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Finding

    11.2. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027

        11.2.1. Biopsy

            11.2.1.1. Bone Marrow Biopsy

            11.2.1.2. Needle Biopsy

            11.2.1.3. Endoscopic Biopsy

        11.2.2. Endoscopy

            11.2.2.1. Bronchoscopy

            11.2.2.2. Colonoscopy

            11.2.2.3. Sigmoidoscopy

            11.2.2.4. Colposcopy

            11.2.2.5. Other

        11.2.3. Imaging

            11.2.3.1. MRI Scan

            11.2.3.2. PET Scan

            11.2.3.3. CT Scan

            11.2.3.4. Mammography

            11.2.3.5. Ultrasound

        11.2.4. Tumor Biomarker Test

            11.2.4.1. PSA Test

            11.2.4.2. CTC Test

            11.2.4.3. AFP Test

            11.2.4.4. CA 19-9

            11.2.4.5. CA 125

            11.2.4.6. EGFR

            11.2.4.7. HER2

            11.2.4.8. CEA

            11.2.4.9. BRCA

            11.2.4.10. KRA

            11.2.4.11. ALK

    11.3. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027

        11.3.1. Blood Cancer

        11.3.2. Breast Cancer

        11.3.3. Colorectal Cancer

        11.3.4. Kidney Cancer

        11.3.5. Liver Cancer

        11.3.6. Lung Cancer

        11.3.7. Ovarian Cancer

        11.3.8. Pancreatic Cancer

        11.3.9. Prostate Cancer

    11.4. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Cancer Diagnostics Market Attractiveness Analysi

        11.5.1. By Method

        11.5.2. By Application

        11.5.3. By Country/Sub-region

12. Latin America Cancer Diagnostics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Finding

    12.2. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027

        12.2.1. Biopsy

            12.2.1.1. Bone Marrow Biopsy

            12.2.1.2. Needle Biopsy

            12.2.1.3. Endoscopic Biopsy

        12.2.2. Endoscopy

            12.2.2.1. Bronchoscopy

            12.2.2.2. Colonoscopy

            12.2.2.3. Sigmoidoscopy

            12.2.2.4. Colposcopy

            12.2.2.5. Other

        12.2.3. Imaging

            12.2.3.1. MRI Scan

            12.2.3.2. PET Scan

            12.2.3.3. CT Scan

            12.2.3.4. Mammography

            12.2.3.5. Ultrasound

        12.2.4. Tumor Biomarker Test

            12.2.4.1. PSA Test

            12.2.4.2. CTC Test

            12.2.4.3. AFP Test

            12.2.4.4. CA 19-9

            12.2.4.5. CA 125

            12.2.4.6. EGFR

            12.2.4.7. HER2

            12.2.4.8. CEA

            12.2.4.9. BRCA

            12.2.4.10. KRA

            12.2.4.11. ALK

    12.3. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027

        12.3.1. Blood Cancer

        12.3.2. Breast Cancer

        12.3.3. Colorectal Cancer

        12.3.4. Kidney Cancer

        12.3.5. Liver Cancer

        12.3.6. Lung Cancer

        12.3.7. Ovarian Cancer

        12.3.8. Pancreatic Cancer

        12.3.9. Prostate Cancer

    12.4. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America Latin America

    12.5. Latin America Cancer Diagnostics Market Attractiveness Analysi

        12.5.1. By Method

        12.5.2. By Application

        12.5.3. By Country/Sub-region

13. Middle East & Africa Cancer Diagnostics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Finding

    13.2. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027

        13.2.1. Biopsy

            13.2.1.1. Bone Marrow Biopsy

            13.2.1.2. Needle Biopsy

            13.2.1.3. Endoscopic Biopsy

        13.2.2. Endoscopy

            13.2.2.1. Bronchoscopy

            13.2.2.2. Colonoscopy

            13.2.2.3. Sigmoidoscopy

            13.2.2.4. Colposcopy

            13.2.2.5. Other

        13.2.3. Imaging

            13.2.3.1. MRI Scan

            13.2.3.2. PET Scan

            13.2.3.3. CT Scan

            13.2.3.4. Mammography

            13.2.3.5. Ultrasound

        13.2.4. Tumor Biomarker Test

            13.2.4.1. PSA Test

            13.2.4.2. CTC Test

            13.2.4.3. AFP Test

            13.2.4.4. CA 19-9

            13.2.4.5. CA 125

            13.2.4.6. EGFR

            13.2.4.7. HER2

            13.2.4.8. CEA

            13.2.4.9. BRCA

            13.2.4.10. KRA

            13.2.4.11. ALK

    13.3. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027

        13.3.1. Blood Cancer

        13.3.2. Breast Cancer

        13.3.3. Colorectal Cancer

        13.3.4. Kidney Cancer

        13.3.5. Liver Cancer

        13.3.6. Lung Cancer

        13.3.7. Ovarian Cancer

        13.3.8. Pancreatic Cancer

        13.3.9. Prostate Cancer

    13.4. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.4.1. GCC Countrie

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa Cancer Diagnostics Market Attractiveness Analysi

        13.5.1. By Method

        13.5.2. By Application

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by Tier and Size of companies)

    14.2. Market Share / Position Analysis, by Company, 2018

    14.3. Competitive Business Strategie

    14.4. Company Profile

        14.4.1. Abbott

            14.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.1.2. Growth Strategie

            14.4.1.3. SWOT Analysi

        14.4.2. Ambry Genetics

            14.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.2.2. Growth Strategie

            14.4.2.3. SWOT Analysi

        14.4.3. AstraZeneca plc

            14.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.3.2. Growth Strategie

            14.4.3.3. SWOT Analysi

        14.4.4. bioMeriux SA

            14.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.4.2. Growth Strategie

            14.4.4.3. SWOT Analysi

        14.4.5. Eli Lilly and Company

            14.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.5.2. Growth Strategie

            14.4.5.3. SWOT Analysi

        14.4.6. Genoptix, Inc

            14.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.6.2. Growth Strategie

            14.4.6.3. SWOT Analysi

        14.4.7. GlaxoSmithKline plc

            14.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.7.2. Growth Strategie

            14.4.7.3. SWOT Analysi

        14.4.8. F. Hoffmann-La Roche Ltd

            14.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.8.2. Growth Strategie

            14.4.8.3. SWOT Analysi

        14.4.9. Pfizer, Inc

            14.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.9.2. Growth Strategie

            14.4.9.3. SWOT Analysis

List of Table

Table 1List of Abbreviation

Table 2Market Snapshot: Global Cancer Diagnostics Market

Table 3List of Cancer Risk Factors

Table 4Estimated Incidence, 1 year, 2 years and 5 years survival

Table 5Breast Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs

Table 6Lung Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs

Table 7Colorectal Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs

Table 8Summary of Type of Diagnostics Test in the U.S.

Table 9Event Impact Analysis: Global Cancer Diagnostics Market, 2017-2027

Table 10Global Cancer Diagnostics Market Revenue, by Method, 2017-2027 (USD) Million

Table 11Global Cancer Diagnostics Market Revenue, by Application, 2017-2027 (USD) Million

Table 12Global Cancer Diagnostics Market Revenue, by Geography, 2017-2027 (USD) Million

List of Figure

Figure 1.Global Cancer Diagnostics Market Segmentation

Figure 2.Global Cancer Diagnostics Market, by Application, 2018 (USD Million)

Figure 3.Comparative Analysis: Global Cancer Diagnostics Market, by Geography, 2018 & 2027E (Value %)

Figure 4.Porter’s Five Forces Analysis: Global Cancer Diagnostics Market

Figure 5.Market Attractiveness Analysis: Global Cancer Diagnostics Market, By Method, 2018 & 2027 (Value %)

Figure 6.Cancer Diagnostics Market: Global Market Share by Key Players, IVDs, Molecular Diagnostics and Companion Diagnostics), 2018 (Value %)

Figure 7.Cancer Diagnostics Market: Global Market Share by Key Players, 2018 (Value %)

Figure 8.Global Prostate Specific Antigen Tests Market Revenue, 2017-2027 (USD Million)

Figure 9.Global Circulating Tumor Cells (CTC) Tests Market Revenue, 2017-2027 (USD Million)

Figure 10.Global Alpha-Fetoprotein (AFP) Tests Market Revenue, 2017-2027 (USD Million)

Figure 11.Global CA 19-9 Tests Market Revenue, 2017-2027 (USD Million)

Figure 12.Global CA-125 Tests Market Revenue, 2017-2027 (USD Million)

Figure 13.Global EGFR Mutation Tests Market Revenue, 2017-2027 (USD Million)

Figure 14.Global HER2 Tests Market Revenue, 2017-2027 (USD Million)

Figure 15.Global Carcinoembryonic Antigen (CEA) Tests Market Revenue, 2017-2027 (USD Million)

Figure 16.Global BRCA Tests Market Revenue, 2017-2027 (USD Million)

Figure 17.Global KRAS Mutation Tests Market Revenue, 2017-2027 (USD Million)

Figure 18.Global Anaplastic Lymphoma Kinase (ALK) Tests Market Revenue, 2017-2027 (USD Million)

Figure 19.MRI Scan Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)

Figure 20.PET Scan Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)

Figure 21.CT Scan Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)

Figure 22.Mammography Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)

Figure 23.Ultrasound Cancer Diagnosis Market Revenue, 2017-2027 (USD Million)

Figure 24.Global Colonoscopy Tests Market Revenue, 2017-2027 (USD Million)

Figure 25.Global Sigmoidoscopy Tests Market Revenue, 2017-2027 (USD Million)

Figure 26.Global Bronchoscopy Tests Market Revenue, 2017-2027 (USD Million)

Figure 27.Global Colposcopy Tests Market Revenue, 2017-2027 (USD Million)

Figure 28.Global Other Endoscopy Tests Market Revenue, 2017-2027 (USD Million)

Figure 29.Global Bone Marrow Biopsy Tests Market Revenue, 2017-2027 (USD Million)

Figure 30.Global Needle Biopsy Tests Market Revenue, 2017-2027 (USD Million)

Figure 31.Global Endoscopic Biopsy Tests Market Revenue, 2017-2027 (USD Million)

Figure 32.Comparative analysis: Global Cancer Diagnostics Market, by Applications, 2018 & 2027 (Value %)

Figure 33.Blood Cancer: Estimated number of new cases, all ages, both sexes (2012, 2015 & 2027)

Figure 34.Global Blood Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)

Figure 51.Comparative Analysis: Global Cancer Diagnostics Market, By Geography, 2018 & 2027 (Value %)

Figure 52.North America Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)

Figure 53.Europe Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)

Figure 54.Asia Pacific Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)

Figure 55.Rest of the World Cancer Diagnostics Market Revenue, 2017-2027 (USD Million)

Figure 56.Abbott Laboratories : Annual Revenue, (USD Million)

Figure 57.Astra Zeneca plc: Annual Revenue, (USD Million)

Figure 58.bioMeriux SA : Annual Revenue, (USD Million)

Figure 59.Eli Lilly and Company: Annual Revenue, (USD Million)

Figure 60.GlaxoSmithKline plc: Annual Revenue, (USD Million)

Figure 61.F. Hoffmann-La Roche Ltd: Annual Revenue, (USD Million)

Figure 62.Pfizer, Inc.: Annual Revenue, (USD Million)

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Cancer Diagnostics Market